Abbott Laboratories
NYSE:ABT

Watchlist Manager
Abbott Laboratories Logo
Abbott Laboratories
NYSE:ABT
Watchlist
Price: 125.46 USD 1.77% Market Closed
Market Cap: 218.2B USD

Intrinsic Value

The intrinsic value of one ABT stock under the Base Case scenario is 114.06 USD. Compared to the current market price of 125.46 USD, Abbott Laboratories is Overvalued by 9%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ABT Intrinsic Value
114.06 USD
Overvaluation 9%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Abbott Laboratories

What is Valuation History?
Ask AI Assistant
What other research platforms think about ABT?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ABT valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Abbott Laboratories.

Explain Valuation
Compare ABT to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Growing regulatory and reputational risks stemming from Abbott’s high-profile infant formula recalls could dampen consumer confidence and potentially lead to stricter oversight of its manufacturing facilities, hindering production and sales growth.

Despite the success of the FreeStyle Libre continuous glucose monitors, increasing competition from Dexcom and Medtronic may compress Abbott’s market share and erode pricing power in the lucrative diabetes care segment.

High exposure to emerging markets through its Established Pharmaceuticals business can subject Abbott to currency volatility and uneven economic conditions, which may constrain profit margins and sales stability.

Bull Theses

Abbott has a leading position in the continuous glucose monitoring market, with its FreeStyle Libre products continuing to gain traction globally, positioning the company for strong long-term revenue growth in diabetes care.

The firm’s robust pipeline of new medical devices, particularly in its structural heart and neuromodulation portfolios, is set to deliver innovative treatments and drive higher-margin revenue streams.

Abbott’s strong nutrition business, which includes brands like Ensure and Pedialyte, provides stable cash flow and brand recognition, helping the company weather cyclical headwinds and fund further growth initiatives.

Show More Less
How do you feel about ABT?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Abbott Laboratories

Current Assets 24.8B
Cash & Short-Term Investments 7.7B
Receivables 8.1B
Other Current Assets 9B
Non-Current Assets 59.3B
Long-Term Investments 951m
PP&E 11.5B
Intangibles 29.6B
Other Non-Current Assets 17.3B
Current Liabilities 14.6B
Accounts Payable 4.1B
Accrued Liabilities 7.6B
Other Current Liabilities 2.8B
Non-Current Liabilities 18.6B
Long-Term Debt 11.6B
Other Non-Current Liabilities 7B
Efficiency

Free Cash Flow Analysis
Abbott Laboratories

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Abbott Laboratories

Revenue
43.8B USD
Cost of Revenue
-19.2B USD
Gross Profit
24.6B USD
Operating Expenses
-16.6B USD
Operating Income
8B USD
Other Expenses
6B USD
Net Income
14B USD
Fundamental Scores

ABT Profitability Score
Profitability Due Diligence

Abbott Laboratories's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Positive 3Y Average ROE
Positive ROIC
Exceptional Gross Margin
62/100
Profitability
Score

Abbott Laboratories's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

ABT Solvency Score
Solvency Due Diligence

Abbott Laboratories's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
72/100
Solvency
Score

Abbott Laboratories's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ABT Price Targets Summary
Abbott Laboratories

Wall Street analysts forecast ABT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABT is 146.81 USD with a low forecast of 123.56 USD and a high forecast of 170.1 USD.

Lowest
Price Target
123.56 USD
2% Downside
Average
Price Target
146.81 USD
17% Upside
Highest
Price Target
170.1 USD
36% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ABT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ABT Insider Trading
Buy and sell transactions by insiders

ABT News

Other Videos
What is the Intrinsic Value of one ABT stock?

The intrinsic value of one ABT stock under the Base Case scenario is 114.06 USD.

Is ABT stock undervalued or overvalued?

Compared to the current market price of 125.46 USD, Abbott Laboratories is Overvalued by 9%.

Back to Top